View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 20, 2022

Walgreens launches new interactive tool to track Covid-19 variants

Walgreens COVID-19 Index identifies the spread of current and emerging Covid-19 variants in real-time.

Walgreens has launched a new interactive tracking tool, the Walgreens COVID-19 Index, to advance the rapid detection of omicron and track variant activity.

The tool uses testing data from Aegis Sciences Corporation and uniquely identifies the spread of current and emerging virus variants in real-time.

The company stated that Walgreens COVID-19 Index can track the spread of the omicron variant within 24 to 48 hours.

The tool offers a snapshot of data for the past seven days based on positive tests analysed at more than 5,000 Walgreens locations across the nation.

According to the data collected and tracked by the tool, more than 95% of all positive cases of Covid-19 nationally are presumed to be the omicron variant.

This reinforces the importance of Covid-19 vaccinations and testing to reduce the spread of the disease.

According to the Walgreens COVID-19 Index, South Dakota, Georgia, Alabama, Nevada, Florida, Mississippi and Texas are the top states for positive Covid-19 case rates.

All of these states have positivity rates of more than 45%.

Walgreens chief medical officer Dr Kevin Ban said: “Through Walgreens’ partnership with Aegis Sciences, we have the ability to provide this interactive tracking tool and inform the development of strategies and resources to help mitigate the spread of Covid-19.

“This provides a leading consumer-centric healthcare solution to support our communities and partners, building on our nationwide footprint and health offerings.”

The Walgreens COVID-19 Index is based on data obtained from PCR test samples collected at specific Walgreens locations and tested by Aegis Sciences.

Aegis Sciences lab operations senior vice-president Dr Matthew Hardison said: “Data regarding spread of variants is important to our understanding of viral transmission and, as new variants emerge, it will be critical to continue to track this information quickly to predict which communities are most at risk.”

Last May, Quidel collaborated with Walgreens to make QuickVue at-home rapid antigen tests available to consumers without a prescription.

Related Companies

Free Report

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy